Krebs Biochemicals & Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
For the nine months, sales was INR 384.49 million compared to INR 406.74 million a year ago. Revenue was INR 386.9 million compared to INR 411.01 million a year ago. Net loss was INR 138.82 million compared to INR 177.52 million a year ago. Basic loss per share from continuing operations was INR 6.44 compared to INR 8.23 a year ago. Diluted loss per share from continuing operations was INR 6.44 compared to INR 8.23 a year ago.